Fractyl Health (GUTS) vs LENSAR (LNSR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LENSAR (LNSR) has outperformed Fractyl Health (GUTS) over the past year, losing 47.0% versus a loss of 74.8%. LENSAR is the larger company by market cap ($78.3 million vs $58.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GUTS | LNSR |
|---|---|---|
| Share price | $4.42 | $6.37 |
| Market cap | $58.63M | $78.26M |
| 1-day change | +4.49% | -1.24% |
| YTD return | -83.98% | -44.54% |
| 1-year return | -74.82% | -47.04% |
| 5-year return | — | -14.23% |
| P/E ratio (TTM) | — | 35.39 |
| EPS (TTM) | $-10.56 | $0.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.34 | $12.94 |
| 52-week low | $4.14 | $4.95 |
| Distance from 52-week high | -84.94% | -50.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1266.52% | +77.86% |
| Average volume | 156.16K | 102.04K |
| Shares outstanding | 13.26M | 12.29M |
| Employees | 100 | 150 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LNSR has outperformed GUTS by 27.8 percentage points over the past year.
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Health Care · Medical/Dental Instruments · 100 employees
About LENSAR
LNSR stock →LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision.
Health Care · Medical/Dental Instruments · 150 employees
GUTS vs LNSR FAQ
Which is bigger, Fractyl Health or LENSAR?
LENSAR (LNSR) is larger, with a market capitalization of $78.26M compared with $58.63M for Fractyl Health (GUTS).
Which stock has performed better over the past year, GUTS or LNSR?
LNSR returned -47.04% over the past 12 months, compared with -74.82% for GUTS (price return, excluding dividends). Past performance does not predict future results.
Are Fractyl Health and LENSAR in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.